PE20170321A1 - Inhibidores de cinasa de interaccion con proteina cinasa activada por mitogeno (mnk) y metodos relacionados con los mismos - Google Patents
Inhibidores de cinasa de interaccion con proteina cinasa activada por mitogeno (mnk) y metodos relacionados con los mismosInfo
- Publication number
- PE20170321A1 PE20170321A1 PE2016002761A PE2016002761A PE20170321A1 PE 20170321 A1 PE20170321 A1 PE 20170321A1 PE 2016002761 A PE2016002761 A PE 2016002761A PE 2016002761 A PE2016002761 A PE 2016002761A PE 20170321 A1 PE20170321 A1 PE 20170321A1
- Authority
- PE
- Peru
- Prior art keywords
- mnk
- activated protein
- interaction
- kinase
- related methods
- Prior art date
Links
- 102000043136 MAP kinase family Human genes 0.000 title abstract 3
- 108091054455 MAP kinase family Proteins 0.000 title abstract 3
- 230000003993 interaction Effects 0.000 title abstract 2
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- YOKQILKYBBHJMR-UHFFFAOYSA-N 6-[(6-aminopyrimidin-4-yl)amino]-8-chloro-1'-methylspiro[2H-imidazo[1,5-a]pyridine-3,4'-piperidine]-1,5-dione Chemical compound CN1CCC2(CC1)NC(=O)C1=C(Cl)C=C(NC3=CC(N)=NC=N3)C(=O)N21 YOKQILKYBBHJMR-UHFFFAOYSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102000001253 Protein Kinase Human genes 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 108060006633 protein kinase Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se refiere a compuestos de formula (I) en donde W1 y W2 son O, S, o N-OR´; R´ es alquilo inferior; Y es -N(R5)-, -O-, entre otros; R1 es H, alquilo inferior, entre otros; n es 1, 2 o 3; R2 y R3 son H, alquilo, entre otros o R2 Y R3 junto a C forman un cicloalquilo o heterociclilo; R4a y R4b son H, halogeno, entre otros; R5 es H, ciano o alquilo inferior o R5 y R8 junto con los atomos a los que estan unidos forman un heterociclilo condensado; R6, R7 y R8 son H, hidroxi, entre otros. Es un compuesto preferido: 6-[(6-aminopirimidin-4-il)amino]-8-cloro-1´-metil-espiro[2H-imidazo[1,5-a]piridin-3,4´-piperidin]-1,5-diona; entre otros. Tambien se refiere a una composicion farmaceutica. Dichos compuestos inhiben la cinasa de interaccion con proteina cinasa activada por mitogeno (Mnk) siendo utiles en el tratamiento de enfermedades tal como cancer
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462017112P | 2014-06-25 | 2014-06-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20170321A1 true PE20170321A1 (es) | 2017-04-05 |
Family
ID=53724447
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2016002761A PE20170321A1 (es) | 2014-06-25 | 2015-06-24 | Inhibidores de cinasa de interaccion con proteina cinasa activada por mitogeno (mnk) y metodos relacionados con los mismos |
Country Status (24)
| Country | Link |
|---|---|
| US (6) | US9382248B2 (es) |
| EP (2) | EP3521289B1 (es) |
| JP (2) | JP6615797B2 (es) |
| KR (1) | KR102460389B1 (es) |
| CN (2) | CN110183449B (es) |
| AU (1) | AU2015279984B2 (es) |
| BR (1) | BR112016029916B1 (es) |
| CA (1) | CA2953365C (es) |
| CL (1) | CL2016003293A1 (es) |
| CO (1) | CO2017000399A2 (es) |
| DK (2) | DK3521289T3 (es) |
| EA (1) | EA033920B1 (es) |
| ES (2) | ES2967536T3 (es) |
| FI (1) | FI3521289T3 (es) |
| IL (1) | IL249557B (es) |
| MX (1) | MX375323B (es) |
| MY (1) | MY189363A (es) |
| NZ (1) | NZ728007A (es) |
| PE (1) | PE20170321A1 (es) |
| PH (1) | PH12016502504B1 (es) |
| SG (2) | SG11201610511YA (es) |
| TW (1) | TWI713455B (es) |
| WO (1) | WO2015200481A1 (es) |
| ZA (1) | ZA201700241B (es) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI713455B (zh) | 2014-06-25 | 2020-12-21 | 美商伊凡克特治療公司 | ＭｎＫ抑制劑及其相關方法 |
| WO2016172010A1 (en) | 2015-04-20 | 2016-10-27 | Effector Therapeutics, Inc. | Inhibitors of immune checkpoint modulators for use in treating cancer and infections |
| EA201891049A1 (ru) | 2015-10-29 | 2018-10-31 | Эффектор Терапьютикс, Инк. | Изоиндолиновые, азаизоиндолиновые, дигидроинденоновые и дигидроазаинденоновые ингибиторы mnk1 и mnk2 |
| WO2017075412A1 (en) | 2015-10-29 | 2017-05-04 | Effector Therapeutics, Inc. | Pyrrolo-, pyrazolo-, imidazo-pyrimidine and pyridine compounds that inhibit mnk1 and mnk2 |
| US10000487B2 (en) | 2015-11-20 | 2018-06-19 | Effector Therapeutics, Inc. | Heterocyclic compounds that inhibit the kinase activity of Mnk useful for treating various cancers |
| US20170191136A1 (en) * | 2015-12-31 | 2017-07-06 | Effector Therapeutics, Inc. | Mnk biomarkers and uses thereof |
| US11261188B2 (en) | 2016-11-28 | 2022-03-01 | Praxis Precision Medicines, Inc. | Fused heteroaryl compounds, and methods thereof for treating diseases, disorders, and conditions relating to aberrant function of a sodium channel |
| CA3045121A1 (en) | 2016-11-28 | 2018-05-31 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| TW201831479A (zh) * | 2017-01-20 | 2018-09-01 | 德商拜耳製藥公司 | 經取代二氫咪唑并吡啶二酮 |
| WO2018134335A1 (en) | 2017-01-20 | 2018-07-26 | Bayer Pharma Aktiengesellschaft | Substituted imidazopyridinpyrimidines |
| WO2018148745A1 (en) * | 2017-02-13 | 2018-08-16 | Praxis Precision Medicines , Inc. | Compounds and their methods of use |
| DK3582776T3 (da) * | 2017-02-14 | 2024-01-08 | Effector Therapeutics Inc | Piperidinsubstituerede mnk-hæmmere og dertil relaterede fremgangsmåder |
| WO2018187480A1 (en) | 2017-04-04 | 2018-10-11 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| WO2018218038A1 (en) | 2017-05-24 | 2018-11-29 | Effector Therapeutics, Inc. | Methods and compositions for cellular immunotherapy |
| CN109020957B (zh) * | 2017-06-12 | 2023-01-13 | 南京天印健华医药科技有限公司 | 作为mnk抑制剂的杂环化合物 |
| WO2019035951A1 (en) | 2017-08-15 | 2019-02-21 | Praxis Precision Medicines, Inc. | COMPOUNDS AND THEIR METHODS OF USE |
| US10793551B2 (en) | 2017-10-19 | 2020-10-06 | Effector Therapeutics Inc. | Benzimidazole-indole inhibitors of Mnk1 and Mnk2 |
| KR102809796B1 (ko) | 2018-05-30 | 2025-05-20 | 프락시스 프리시젼 메디신즈, 인크. | 이온 채널 조절인자 |
| EA202092908A1 (ru) | 2018-09-28 | 2021-05-14 | Праксис Пресижн Медсинз, Инк. | Модуляторы ионных каналов |
| CN113286592A (zh) | 2018-10-24 | 2021-08-20 | 效应治疗股份有限公司 | Mnk抑制剂的结晶形式 |
| CN111253397B (zh) * | 2018-11-30 | 2023-11-14 | 上海迪诺医药科技有限公司 | Mnk抑制剂 |
| CN111484494B (zh) | 2019-01-29 | 2022-09-13 | 诺沃斯达药业(上海)有限公司 | 抑制mnk1和mnk2的多环化合物 |
| WO2020237167A1 (en) * | 2019-05-23 | 2020-11-26 | Board Of Regents, The University Of Texas System | Inhibitor of mnk for the treatment of neuropathic pain |
| US11773099B2 (en) | 2019-05-28 | 2023-10-03 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| US11279700B2 (en) | 2019-05-31 | 2022-03-22 | Praxis Precision Medicines, Inc. | Ion channel modulators |
| US11505554B2 (en) | 2019-05-31 | 2022-11-22 | Praxis Precision Medicines, Inc. | Substituted pyridines as ion channel modulators |
| WO2021003157A1 (en) | 2019-07-02 | 2021-01-07 | Effector Therapeutics, Inc. | Eif4e-inhibiting 4-oxo-3,4-dihydropyrido[3,4-d]pyrimidine compounds |
| TW202114681A (zh) | 2019-07-02 | 2021-04-16 | 美商ｅＦＦＥＣＴＯＲ醫療公司 | 轉譯抑制劑及其用途 |
| WO2021016263A1 (en) * | 2019-07-21 | 2021-01-28 | University Of Virginia Patent Foundation | Cysteine binding compositions and methods of use thereof |
| HRP20241540T1 (hr) * | 2019-11-18 | 2025-01-03 | Jumbo Drug Bank Co., Ltd. | Pirolotriazinski spojevi koji djeluju kao inhibitor mnk |
| US11767325B2 (en) | 2019-11-26 | 2023-09-26 | Praxis Precision Medicines, Inc. | Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators |
| MX2022016516A (es) * | 2020-06-30 | 2023-03-28 | 4E Therapeutics Inc | Piridina-1,5-dionas que exhiben inhibición de proteínas cinasas activadas por mitogenos que interaccionan con cinasas activadas (mnk) y su método de uso. |
| WO2022038563A1 (en) * | 2020-08-20 | 2022-02-24 | Hepagene Therapeutics (HK) Limited | Mnk inhibitors |
| US11925642B2 (en) | 2020-10-08 | 2024-03-12 | Board Of Regents, The University Of Texas System | Regulation of eIF4E activity for migraine therapy |
| JP7638031B2 (ja) * | 2021-05-08 | 2025-03-03 | 成都嘉葆薬銀医薬科技有限公司 | ピロロトリアジン系化合物の塩形、その結晶形及びその製造方法 |
| IL309668A (en) * | 2021-06-30 | 2024-02-01 | 4E Therapeutics Inc | Spirocyclic pyridine-5,1-diones exhibiting MNK inhibition and a method for their use |
| JP2024528982A (ja) * | 2021-08-05 | 2024-08-01 | ４イー セラピューティクス， インコーポレイテッド | Ｍｎｋ阻害剤による片頭痛の治療方法 |
| CN114853756B (zh) * | 2022-03-31 | 2023-03-28 | 武汉九州钰民医药科技有限公司 | 化合物Tomivosertib的制备工艺 |
| CN114671869B (zh) * | 2022-03-31 | 2023-06-30 | 武汉九州钰民医药科技有限公司 | 化合物Tomivosertib的合成方法 |
| CN114736205B (zh) * | 2022-03-31 | 2023-03-03 | 武汉九州钰民医药科技有限公司 | 化合物Tomivosertib的制备方法 |
| WO2024017229A1 (zh) * | 2022-07-19 | 2024-01-25 | 成都嘉葆药银医药科技有限公司 | 一种吡咯并三嗪类化合物在制备抗肿瘤药物中的应用 |
| CN116425750A (zh) * | 2023-02-10 | 2023-07-14 | 诺沃斯达药业(上海)有限公司 | 一种mnk抑制剂化合物的盐、晶体及其制备方法 |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| WO2025034702A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Rmc-6291 for use in the treatment of ras protein-related disease or disorder |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025190364A1 (zh) * | 2024-03-14 | 2025-09-18 | 山东轩竹医药科技有限公司 | Kif18a抑制剂及其用途 |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5491144A (en) | 1991-05-30 | 1996-02-13 | Ciba-Geigy Corporation | Substituted diaminophthalimides and analogues |
| US9357797B2 (en) * | 1999-11-06 | 2016-06-07 | Janmarie Hornack | Dietary supplement containing alkaline electrolyte buffers |
| DE60219788T2 (de) * | 2001-06-05 | 2008-01-17 | Lilly Icos Llc, Wilmington | Tetrazyklische verbindungen als pde5-inhibitoren |
| TWI301760B (en) | 2004-02-27 | 2008-10-11 | Merz Pharma Gmbh & Co Kgaa | Tetrahydroquinolinones and their use as antagonists of metabotropic glutamate receptors |
| US7488745B2 (en) | 2004-07-16 | 2009-02-10 | Schering Corporation | Compounds for the treatment of inflammatory disorders |
| TW200613272A (en) | 2004-08-13 | 2006-05-01 | Astrazeneca Ab | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators |
| JP2009509921A (ja) | 2005-08-12 | 2009-03-12 | アストラゼネカ アクチボラグ | 置換イソインドロン類及び代謝調節型グルタミン酸受容体増強剤としてのその使用 |
| CA2654358A1 (en) * | 2006-06-22 | 2007-12-27 | Biovitrum Ab (Publ) | Pyridine and pyrazine derivatives as mnk kinase inhibitors |
| EP1889847A1 (en) * | 2006-07-10 | 2008-02-20 | DeveloGen Aktiengesellschaft | Pyrrolopyrimidines for pharmaceutical compositions |
| DK2134689T3 (da) | 2007-03-16 | 2014-06-30 | Scripps Research Inst | Inhibitorer af fokal adhæsionskinase |
| GB0706072D0 (en) | 2007-03-28 | 2007-05-09 | Sterix Ltd | Compound |
| JP2009173629A (ja) | 2007-12-21 | 2009-08-06 | Banyu Pharmaceut Co Ltd | Ｒｓｋ１阻害作用を有する新規スピロインダン誘導体 |
| WO2009112445A1 (en) | 2008-03-10 | 2009-09-17 | Novartis Ag | Method of increasing cellular phosphatidyl choline by dgat1 inhibition |
| JP5675614B2 (ja) * | 2008-08-26 | 2015-02-25 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 医薬組成物用のチエノピリミジン |
| US8637525B2 (en) | 2009-07-31 | 2014-01-28 | Bristol-Myers Squibb Company | Compounds for the reduction of beta-amyloid production |
| TWI468402B (zh) | 2009-07-31 | 2015-01-11 | 必治妥美雅史谷比公司 | 降低β－類澱粉生成之化合物 |
| TWI393716B (zh) | 2009-08-04 | 2013-04-21 | Merck Sharp & Dohme | 作為ｉｘａ因子抑制劑之雜環化合物 |
| WO2011106168A1 (en) | 2010-02-24 | 2011-09-01 | Dcam Pharma Inc | Purine compounds for treating autoimmune and demyelinating diseases |
| PE20140165A1 (es) | 2010-10-01 | 2014-02-26 | Bayer Ip Gmbh | Combinaciones que contienen n-(2-arilamino)arilsulfonamida |
| WO2012075140A1 (en) | 2010-11-30 | 2012-06-07 | Pharmasset, Inc. | Compounds |
| US9938269B2 (en) | 2011-06-30 | 2018-04-10 | Abbvie Inc. | Inhibitor compounds of phosphodiesterase type 10A |
| WO2013043192A1 (en) | 2011-09-23 | 2013-03-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Galactokinase inhibitors for the treatment and prevention of associated diseases and disorders |
| EP2797927B1 (en) | 2011-12-30 | 2019-09-25 | Hanmi Pharm. Co., Ltd. | THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES |
| CA2868966C (en) | 2012-03-29 | 2021-01-26 | Francis Xavier Tavares | Lactam kinase inhibitors |
| US10280168B2 (en) | 2012-03-30 | 2019-05-07 | Agency For Science, Technology And Research | Bicyclic heteroaryl derivatives as MNK1 and MNK2 modulators and uses thereof |
| GB201205669D0 (en) | 2012-03-30 | 2012-05-16 | Agency Science Tech & Res | Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof |
| WO2013151975A1 (en) | 2012-04-02 | 2013-10-10 | Northeastern University | Compositions and methods for the inhibition of methyltransferases |
| WO2013174743A1 (en) * | 2012-05-21 | 2013-11-28 | Bayer Pharma Aktiengesellschaft | Substituted pyrrolopyrimidines |
| TW201412740A (zh) * | 2012-09-20 | 2014-04-01 | Bayer Pharma AG | 經取代之吡咯并嘧啶胺基苯并噻唑酮 |
| JP6306035B2 (ja) * | 2012-11-09 | 2018-04-04 | エヴォテック・インターナショナル・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＥｖｏｔｅｃ Ｉｎｔｅｒｎａｔｉｏｎａｌ ＧｍｂＨ | 医薬組成物のためのスルホキシミン置換キナゾリン |
| GB2508652A (en) | 2012-12-07 | 2014-06-11 | Agency Science Tech & Res | Heterocyclic piperazine derivatives |
| WO2014099941A1 (en) | 2012-12-19 | 2014-06-26 | Idenix Pharmaceuticals, Inc. | 4'-fluoro nucleosides for the treatment of hcv |
| EP2958920A1 (en) | 2013-02-20 | 2015-12-30 | Bayer Pharma Aktiengesellschaft | Substituted-imidazo[1,2-b]pyridazines as mknk1 inhibitors |
| TW201605867A (zh) | 2013-11-20 | 2016-02-16 | 拜耳製藥公司 | 噻吩并嘧啶 |
| TWI713455B (zh) | 2014-06-25 | 2020-12-21 | 美商伊凡克特治療公司 | ＭｎＫ抑制劑及其相關方法 |
| EP3233866B1 (en) * | 2014-12-19 | 2021-04-21 | Bayer Pharma Aktiengesellschaft | Pyrazolopyridinamines as mknk1 and mknk2 inhibitors |
| WO2017075412A1 (en) | 2015-10-29 | 2017-05-04 | Effector Therapeutics, Inc. | Pyrrolo-, pyrazolo-, imidazo-pyrimidine and pyridine compounds that inhibit mnk1 and mnk2 |
| EA201891049A1 (ru) | 2015-10-29 | 2018-10-31 | Эффектор Терапьютикс, Инк. | Изоиндолиновые, азаизоиндолиновые, дигидроинденоновые и дигидроазаинденоновые ингибиторы mnk1 и mnk2 |
| GB201520500D0 (en) | 2015-11-20 | 2016-01-06 | Medical Res Council Technology | Compounds |
| US10000487B2 (en) | 2015-11-20 | 2018-06-19 | Effector Therapeutics, Inc. | Heterocyclic compounds that inhibit the kinase activity of Mnk useful for treating various cancers |
| GB201520499D0 (en) | 2015-11-20 | 2016-01-06 | Medical Res Council Technology | Compounds |
-
2015
- 2015-06-23 TW TW104120090A patent/TWI713455B/zh active
- 2015-06-24 CN CN201910556784.9A patent/CN110183449B/zh active Active
- 2015-06-24 WO PCT/US2015/037416 patent/WO2015200481A1/en not_active Ceased
- 2015-06-24 US US14/748,990 patent/US9382248B2/en active Active
- 2015-06-24 MX MX2016017030A patent/MX375323B/es active IP Right Grant
- 2015-06-24 DK DK19158973.8T patent/DK3521289T3/da active
- 2015-06-24 KR KR1020177002139A patent/KR102460389B1/ko active Active
- 2015-06-24 PH PH1/2016/502504A patent/PH12016502504B1/en unknown
- 2015-06-24 EA EA201790078A patent/EA033920B1/ru not_active IP Right Cessation
- 2015-06-24 FI FIEP19158973.8T patent/FI3521289T3/fi active
- 2015-06-24 MY MYPI2016704761A patent/MY189363A/en unknown
- 2015-06-24 SG SG11201610511YA patent/SG11201610511YA/en unknown
- 2015-06-24 AU AU2015279984A patent/AU2015279984B2/en active Active
- 2015-06-24 JP JP2016575379A patent/JP6615797B2/ja active Active
- 2015-06-24 CN CN201580046203.7A patent/CN106795162B/zh active Active
- 2015-06-24 CA CA2953365A patent/CA2953365C/en active Active
- 2015-06-24 ES ES19158973T patent/ES2967536T3/es active Active
- 2015-06-24 PE PE2016002761A patent/PE20170321A1/es unknown
- 2015-06-24 NZ NZ728007A patent/NZ728007A/en unknown
- 2015-06-24 EP EP19158973.8A patent/EP3521289B1/en active Active
- 2015-06-24 BR BR112016029916-7A patent/BR112016029916B1/pt active IP Right Grant
- 2015-06-24 DK DK15742147.0T patent/DK3160966T3/da active
- 2015-06-24 ES ES15742147T patent/ES2728201T3/es active Active
- 2015-06-24 EP EP15742147.0A patent/EP3160966B1/en active Active
- 2015-06-24 SG SG10201811384TA patent/SG10201811384TA/en unknown
-
2016
- 2016-06-21 US US15/187,854 patent/US9669031B2/en active Active
- 2016-12-14 IL IL249557A patent/IL249557B/en unknown
- 2016-12-22 CL CL2016003293A patent/CL2016003293A1/es unknown
-
2017
- 2017-01-11 ZA ZA2017/00241A patent/ZA201700241B/en unknown
- 2017-01-18 CO CONC2017/0000399A patent/CO2017000399A2/es unknown
- 2017-06-02 US US15/611,966 patent/US9814718B2/en active Active
- 2017-11-10 US US15/809,011 patent/US20180085368A1/en not_active Abandoned
-
2018
- 2018-11-02 US US16/178,678 patent/US20190209560A1/en not_active Abandoned
-
2019
- 2019-11-06 JP JP2019201631A patent/JP6979439B2/ja active Active
-
2021
- 2021-05-05 US US17/308,486 patent/US20210338673A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20170321A1 (es) | Inhibidores de cinasa de interaccion con proteina cinasa activada por mitogeno (mnk) y metodos relacionados con los mismos | |
| PE20191349A1 (es) | Inhibidores de mnk sustituidos con piperidina y metodos relacionados con los mismos | |
| PE20161251A1 (es) | Compuestos heteroarilo o arilo biciclicos fusionados y su uso como inhibidores de irak4 | |
| PE20171307A1 (es) | Compuestos de triazolopirimidina y usos de los mismos | |
| UY37926A (es) | Formulaciones de 6-(2-hidroxi-2-metilpropoxi)-4-(6-(6-((6-metoxipiridin-3-il)metil)-3,6-diazabiciclo[3.1.1]heptan-3-il)piridin-3-il)pirazolo[1,5-a]piridina-3-carbonitrilo | |
| CL2017001426A1 (es) | Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales. | |
| PE20161066A1 (es) | Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos | |
| PE20191245A1 (es) | Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim | |
| PE20191613A1 (es) | Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret | |
| PE20190515A1 (es) | Peptidos modificados de auristatina y conjugados anticuerpo-farmaco de los mismos | |
| CL2018000292A1 (es) | Compuestos farmacéuticos | |
| PE20152033A1 (es) | Heterociclos bicicliclos como inhibidores de fgfr | |
| PE20131164A1 (es) | IMIDAZOPIRIDAZINAS SUSTITUIDAS COMO INHIBIDORES DE LA QUINASA Mps-1 | |
| PE20170403A1 (es) | COMPUESTOS DE IMIDAZO[4,5-c]QUINOLIN-2-ONA Y SU USO PARA TRATAR CANCER | |
| DOP2018000065A (es) | Derivados de 8-[6-[3-(amino)propoxi]-3-piridil]1-isopropilimidazo[4,5-c]quinolin-2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm) para el tratamiento del cáncer | |
| AR106037A1 (es) | Moduladores de la proteína core de la hepatitis b | |
| CL2013003344A1 (es) | Compuestos derivados de piridin-2(1h)-ona sustituidos, inhibidores de quinasas jak; composicion farmaceutica que los comprende; combinacion farmaceutica; utiles en el tratamiento de enfermedades mieloproliferatavas, leucemia, rechazo de trasplantes, enfermedades mediadas por el sistema inmune, entre otras. | |
| PE20170666A1 (es) | 2-(morfolin-4-il)-1,7-naftiridinas | |
| PE20130306A1 (es) | Morfolinopirimidinas y su uso en terapia | |
| ECSP18003372A (es) | Compuestos tricíclicos y su uso como inhibidores de la fosfodiesterasa | |
| PE20141282A1 (es) | Derivados de 8-carbamoil-2-(2,3-pirid-6-ilo di sustituido)-1,2,3,4-tetrahidroisoquinolina como agentes inductores de la apoptosis para el tratamiento del cancer y enfermedades inmunes y autoinmunes | |
| PE20120224A1 (es) | Derivados de 1h-imidazo-[4,5-c]-quinolinona | |
| PE20120534A1 (es) | PIRIMIDINAS FUSIONADAS COMO INHIBIDORES DE Akt | |
| PE20180024A1 (es) | Triazolopirazinonas como inhibidores de pde1 | |
| PE20141553A1 (es) | Compuestos de triazolopiridina como inhibidores de la ped10a |